Protagonist Therapeutics
PTGX
34 hedge funds and large institutions have $145M invested in Protagonist Therapeutics in 2016 Q3 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFA
26
Nationwide Fund Advisors
Columbus,
Ohio
| $44K | +$28.7K | +2,101 | New |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $26K | +$17.4K | +1,270 | New |
|
28
UBS Group
Zurich,
Switzerland
| $23K | +$14.6K | +1,069 | New |
|
29
Citigroup
New York
| $13K | +$8.49K | +621 | New |
|
30
BNP Paribas Financial Markets
Paris,
France
| $5.73K | +$3.7K | +271 | New |
|
31
Creative Planning
Overland Park,
Kansas
| $4K | +$2.42K | +177 | New |
|
32
Morgan Stanley
New York
| $4K | +$2.73K | +200 | New |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$2.73K | +200 | New |
|
|
TCIM
34
TIAA CREF Investment Management
New York
| $213 | +$138K | +10,093 | New |
|
PTGX Hedge Fund Activity: Q3 2016 in Review
34 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2016, worth a combined $145M.
Buyers outnumbered sellers: 34 funds opened new PTGX positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $29.1M.
- 34 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2016, up from 0 in Q2 2016.
- Funds reported $145M of Protagonist Therapeutics stock for Q3 2016.
- 34 funds opened new Protagonist Therapeutics positions in Q3 2016 and 0 closed out, a net change of +34 holders.
- The largest Protagonist Therapeutics buyer in Q3 2016 was Fidelity Investments, an estimated $29.1M added.
Based on aggregated 13F filings for Q3 2016.